Binding of Thrombin to Fibrin

1979 ◽  
Author(s):  
L. Róka ◽  
F. G. Rademacher

After clot formation using bovine thrombin and bovine fibrinogen, one can detect no longer the total amount of thrombin. The amount missing in the supernatant is trapped in the clot and can be removed in active state after lysing the clot. The capacity for trapping thrombin by a constant amount of fibrin depends on the structure of the fibrinpolymer. This can be shown by producing different kinds of clots by variation of pH or monomer concentration during polymerisation or using Arvinmonomer insted of Thrombinmonomer. The trapped thrombin shows no clotting activity but some activity with chromogenic substrats remains. to neutralize trapped thrombin about 5 times more antithrombin III is necessary than for the same amount of free thrombin. The trapped thrombin diffuses out of the clot indicating the reversibility of the binding of thrombin to fribin.

1979 ◽  
Author(s):  
L. Róka ◽  
F.G. Rademacher

After clot formation using bovine thrombin and bovine fibrinogen, one can detect no longer the total amount of thrombin. The amount missing in the supernatant is trapped in the clot and can be removed in active state after lysing the clot. The capacity for trapping thrombin by a constant amount of fibrin depends on the structure of the fibrinpolymer. This can be shown by producing different kinds of clots by variation of pH or monomer concentration during polymerisation or using Arvinmonomer insted of Thrombinmonomer. The trapped thrombin shows no clotting activity but some activity with chromogenic substrats remains. To neutralize trapped thrombin about 5 times more Antithrombin III is necessary than for the same amount of free thrombin. The trapped thrombin diffuses out of the clot indicating the reversibility of the binding of thrombin to fribin.


1979 ◽  
Author(s):  
E. E. Czapek ◽  
H. C. Kwaan

The platelet has been implicated as the nidus around which clot formation occurs. We therefore decided to investigate whether any antithrombotic activity was associated with platelets. Thrombin activity was measured using the chromogenic substrate S-2238. Freshly prepared human platelet rich plasma (PRP) and platelet poor plasma (PPP) were found to have similar amounts of antithrombin activity. This antithrombin activity could be easily removed from a platelet pellet by repeated washing. However, sonicating PRP resulted in the appearance of additional antithrombin activity. After 6 minutes of sonication, the antithrombin activity of PRP decreased to 35% of presonication levels, whereas the antithrombin activity of PPP remained 100%. When subjected to Laurell Immunoelectrophoresis using an antibody to antithrombin III (AT-III), a greater amount of antigen was detected in PRP than in PPP. We conclude that platelets contain antithrombin material which is probably AT-III.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1075-1075
Author(s):  
Michael Adam Meledeo ◽  
Armando C Rodriguez ◽  
Chet R Voelker ◽  
James A Bynum ◽  
Andrew P Cap

Abstract Introduction The acute traumatic coagulopathy (ATC) which develops within 30 min following severe trauma with tissue damage and shock is defined by an increased prothrombin time (PT) and international normalized ratio (INR). While reduced thrombin might be expected in conjunction with elevated PT, recent clinical studies reveal paradoxically elevated thrombin generation potential in patients with ATC. We therefore hypothesized that the quantity of thrombin and the timing of thrombin-fibrinogen interactions both have an impact on clot quality; the exuberant production of thrombin found in trauma results in improper clot formation. Methods In vitro studies were conducted in human blood products and simplified synthetic plasma (consisting of purified human coagulation factors in HEPES buffered saline). Turbidimetry was used to observe fibrin crosslinking, while thromboelastography (TEG) was used to quantify clot formation parameters. Quantitation of fibrin(ogen) degradation products (FDPs) was conducted with the STA-R Evolution coagulation analyzer and by ELISA. A fluorogenic substrate was used to observe thrombin generation. Results Increasing the amount of prothrombin or thrombin (0-1400nM) in prothrombin-immunodepleted citrated plasma resulted in reduced clot times. The same dose response was examined in a buffered mixture of fibrinogen (300 mg/dl), FXIII (31.25nM), Ca2+ (2mM), and FXa (170nM-only used with prothrombin samples). However, while increasing prothrombin increased clot strength in both FII-deficient plasma and in the synthetic plasma, direct addition of thrombin decreased clot strength and by 3-fold at 1000nM versus 100nM (Figure 1; *p<0.05; **p<0.01; ***p<0.001 between groups at given concentration); fibrin density was similarly reduced in turbidimetric assays. In TEG, the thrombin dose response did not affect whole blood or platelet-rich plasma, but in platelet-poor plasma the same clot strength inhibition trend was observed. Thrombin generation from the combination of prothrombin (0-1000 nM), FXa (170 nM), and Ca2+ (2 mm) was found to be saturated above an initial prothrombin concentration of 500nM. An examination of FDPs from plasmin-degraded fibrinogen ± thrombin ± FXIII showed that FDPs from both crosslinked and uncrosslinked fibrin had 4-fold higher amounts of fibrin monomer and D-dimer than those produced from plasmin digestion of pure fibrinogen. When FDPs from thrombin +fibrinogen ± FXIII were supplemented back into fresh fibrinogen (0-50% of the final mixture) and allowed to clot again, there was a concentration-dependent decrease in fibrin formation rate (control: 0.15 OD/min; 50% FDP: 0.07 OD/min; p<0.001) which was not observed in samples treated with non-thrombin exposed FDPs. The use of these FDPs allowed for simulations of trauma patient plasma to be constructed using concentrations of plasma proteins associated with both "normal" trauma and the hypocoagulable state which manifests in ATC. When combining relevant levels of thrombin, fibrinogen, FDPs, and antithrombin III as are found in trauma patients that trend toward either good or bad outcomes, differences in TEG tracings can be observed illustrating the validity of these in vitro systems (Figure 2). Conclusions The dose responses of prothrombin versus thrombin reveal the significance of the timing of these reactions on proper clot formation. The conversion of prothrombin to thrombin mediated through FXa and FVa results in strong clots under normal circumstances. These results were reflected in both turbidimetry and TEG, indicating that fibrin crosslinking is being hindered by the presence of excess thrombin even in the presence of the antithrombin III. Additionally, FDPs from crosslinked substrates reduce new clot-making efficiency. Excess thrombin and significant increases in FDPs (which can result from fibrinolytic feedback loops) both contribute to an in vitro phenotype that may represent an underlying factor in the development of ATC. Disclosures No relevant conflicts of interest to declare.


PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0249209
Author(s):  
Bogdan Neculaes ◽  
Andrew L. Frelinger ◽  
Anja J. Gerrits ◽  
Thomas Gremmel ◽  
Emma E. Forde ◽  
...  

Activated platelet-rich plasma (PRP) has been used in the clinical settings of wound healing and regenerative medicine, with activation typically induced by the addition of bovine thrombin. To eliminate issues with availability, cost and potential side effects associated with bovine thrombin, ex vivo PRP activation using pulse electric fields (PEF) has been proposed and demonstrated. The present study characterizes the effect of PEF voltage and pulse width, in combination with a range of calcium concentrations, on clot formation, growth factor release, and serotonin (5-HT) release from dense granules. The main findings are: 1) increasing calcium concentrations with most PEF conditions leads to increased levels of PDGF and 5-HT release; 2) whether EGF levels increase or decrease with increasing calcium concentration depends on the specific PEF parameters; 3) the pattern of PDGF and EGF levels in supernatants suggest that these molecules are localized differently within platelets; 4) significant levels of PDGF, EGF, and 5-HT can be released without inducing clot formation or hemoglobin release. In conclusion, voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin from PEF-activated PRP. Because growth factor requirements vary for different types of wounds and for wounds at different stages of healing, the unique balance of factors in supernatants of PEF-activated PRP may provide more clinically advantageous than the current standard of bovine thrombin-activated PRP.


1973 ◽  
Vol 30 (01) ◽  
pp. 106-113 ◽  
Author(s):  
Linda Nahas ◽  
Ferruccio Betti ◽  
Aura S. Kamiguti ◽  
Hissae Sato

SummaryExperiments with plasmas samples from the snake B. jararaca and X. merremii have shown that the two differ markedly with respect to their reaction to bovine thrombin. The plasma of X. merremii appears to react in a manner very similar to that of normal human plasma both using the thrombin clotting test and using the antithrombin III assay of Astrup and Darling (Biggs and Macfariane 1962). The plasma of B. jararaca on the other hand, contains, in addition to antithrombin III, an inhibitor which resembles mammalian heparin. This inhibitor prolongs the thrombin clotting time of human and X. merremii plasmas, is recorded by the antithrombin assay and is neutralized by protamine. The inhibitor is however, not identical with mammalian heparin since it is not adsorbed by BaSO4 and Al(OH)3 (which adsorb heparin) and it is heat labil whereas mammalian heparin is heat stable.


1981 ◽  
Vol 199 (3) ◽  
pp. 521-526 ◽  
Author(s):  
Raymund Machovich ◽  
Pál I. Bauer ◽  
Péter Arányi ◽  
Éva Kecskés ◽  
Kálmán G. Büki ◽  
...  

Inactivation of plasmin by a 3–4-fold molar excess of antithrombin III follows pseudo-first-order kinetics and the apparent rate constants are proportional to the concentration of the inhibitor. Heparin accelerates the inactivation reaction without changing its pseudo-first-order character, and the apparent rate constants are also proportional to the concentration of the polysaccharide. Heparin results in a minimum 20-fold rate enhancement of the reaction between plasmin and antithrombin III when the concentrations of heparin and plasmin are approx. 0.5mum and 1mum respectively. Heparin at a molar concentration well below that of plasmin still accelerates the reaction: one molecule of the polysaccharide is able to facilitate the inactivation of about 100 molecules of plasmin. Heparin must bind to plasmin to accelerate the plasmin–antithrombin III reaction, since the modification of four to five lysine residues of the enzyme inhibits the rate-enhancement effect of heparin and the dissociation of heparin–plasmin complex decreases the inactivation rate of plasmin. Increasing the concentration of antithrombin III, at a constant amount of heparin, results in increase of the inactivation rate. By contrast, the effect of increasing the amount of plasmin in the presence of constant amount of heparin and antithrombin III is such that higher plasmin-to-heparin ratios are associated with lower rates of inactivation. It seems, therefore, that to obtain ‘optimal’ conditions for fast enzyme inactivation, the amount of heparin should be matched to plasmin rather than to antithrombin III. Arrhenius plots of the plasmin–antithrombin III reaction are linear both in the absence and presence of heparin, at concentrations of 1 or 2mug/ml, over a range of 26K. Under these experimental conditions, heparin increases activation entropy. The findings show that heparin seems to fulfil some criteria that are characteristic for biological catalysis: binding, reaction-rate enhancement (increasing activation entropy), recycling of heparin (effectiveness of non-stoichiometric amounts of the polysaccharide) and specificity.


1977 ◽  
Author(s):  
W.H. Holleman ◽  
L.J. Coen ◽  
J.O. Capobianco ◽  
G.H. Barlow

Methods were developed for the isolation of gm. quantities of human antithrombin-III (AT-III) from Cohn Fraction IV-1 of human plasma using heparin covalently attached to agarose. Attachment of heparin carboxyl groups to alkylamino-agarose yielded a support with no affinity for AT-III. Linkage via the heparin hydroxyl groups yielded a support with approximately 1 mg of heparin/ml agarose and with a low capacity for binding AT-III. Linkage of heparin to agarose thru its amino groups yielded a heparin-agarose with the highest capacity for AT-III. Reaction of heparin containing a free α-amino group with cyanogen bromide activated agarose resulted in agarose substituted with 5 mg of heparin/ml. The conditions of buffer, pH, ionic strength and temperature which maximized AT-III binding were 0.05M sodium phosphate, 0.02M sodium citrate, 0.15M NaCl, pH 8.3 and 4°. The heparin-agarose bound 0.1-0.2 mg of AT-IIl/ml. The AT-III isolated by affinity chromatography was further purified by gel permeation and yielded a homogeneous product as judged by Polyacrylamide disc gel electrophoresis of native and reduced protein and by sedimentation velocity (S20, w = 4.1). This material had an activity of 1700 units/A280 as measured by inhibition of human thrombin. The AT-III is stable to heating at 60° for 10 hours in a buffer of 0.5M sodium citrate at pH 7-8. Injection of bovine thrombin (3000 units/Kg) into heparinized dogs (150 units/Kg) decreased circulating AT-III levels to 50%. (Supported by NHLI, Contract NOl-HB-4-2946).


Blood ◽  
1996 ◽  
Vol 88 (9) ◽  
pp. 3432-3445 ◽  
Author(s):  
MD Rand ◽  
JB Lock ◽  
C van't Veer ◽  
DP Gaffney ◽  
KG Mann

The sequences of events regulating thrombin generation during tissue factor-initiated clotting in whole blood at 37 degrees C in which the contact pathway was suppressed with corn trypsin inhibitor are studied using quantitative Western blotting of factor V, prothrombin, platelet factor 4, antithrombin III, and fibrinogen. In addition, fibrinopeptide A (FPA), thrombin-antithrombin III (TAT) complex formation, and prothrombin fragment 1.2 (F1.2) were measured via commercially available enzyme-linked immunosorbent assays (ELISAs). In a typical experiment initiated with 40 pmol/L recombinant tissue factor, visual clot time (4.5 minutes), was preceded by significant cleavage of factor V resulting in 65% factor Va heavy-chain generation but only 10% light-chain formation. At this point, 50% of the platelet factor 4 is released, suggesting that half (approximately 700 pmol/L) of the platelet prothrombinase sites available have been generated. At clot time, approximately 15 nmol/L thrombin B-chain is present; however, analyses of FPA release demonstrate that only 15% of the thrombin is acting on fibrinogen. This thrombin is produced by the action of 7 pmol/L prothrombinase. The maximum rate of thrombin production is reached well after clot time and is consistent with the presence of approximately 150 pmol/L prothrombinase (at about 7 minutes). These results suggest that factor Xa is the limiting factor for thrombin generation. After 60 minutes, 75% of the initial prothrombin (1.24 mumol/L) is consumed yielding 400 nmol/ L prethrombin 2 and 360 nmol/l thrombin (B-chain) products. The sum of these values (800 nmol/L) is similar to the (corrected) F1.2 concentration determined by ELISA. The incomplete cleavage of prothrombin indicates both the prothrombinase complex and the formation of prothrombinase are inhibited in the reaction. TAT complex measured by ELISA is almost equivalent to B-chain concentration, but sodium dodecyl sulfate stable thrombin-antithrombin III complexes are not observed until well after clot formation and are never equivalent to ELISA-TAT values. At the point of clot formation, 80% of the fibrinogen is depleted from the fluid phase, whereas only 35% to 45% of the FPA is released, suggesting a significant incorporation of uncleaved fibrinogen into the initial clot formed.


1979 ◽  
Author(s):  
E.E. Czapek ◽  
H.C. Kwaan

The platelet has been implicated as the nidus around which clot formation occurs. We therefore decided to investigate whether any antithrombotic activity was associated with platelets. Thrombin activity was measured using the chromogenic substrate S-2238. Kreshly prepared human platelet rich plasma (PRP) and platelet poor plasma (PPP) were found to have similar amounts of antithrombin activity. This antithrombin activity could be easily removed from a platelet pellet by repeated washing. However, sonicating PRP resulted in the appearance of additional antithrombin activity. After 6 minutes of sonlcation, the antithrombin activity of PRP decreased to 35% of presonication levels, whereas the antithrombin activity of PPP remained 100%. When subjected to Laurell immunoelectrophoresis using an antibody to antithrombin III(AT-III), a greater amount of antigen was detected in PRP than in PPP. We conclude that platelets contain antithrombin material which is probably AT-III.


Sign in / Sign up

Export Citation Format

Share Document